免疫疗法在晚期非小细胞肺癌中与年龄相关的疗效:一个全面的元分析
Yao Ding1, Shun Lei2, Ling Wang1
1Phase I Clinical Trial Ward, Chongqing University Cancer Hospital, Chongqing 400030, China.
Lung cancer (Amsterdam, Netherlands)
|August 15, 2024
概括
患有非小细胞肺癌 (NSCLC) 的老年患者 (75岁以上) 经历了与年轻患者相似的免疫治疗益处. 这一元分析证实免疫检查点抑制剂 (ICI) 在不同年龄组对NSCLC治疗同样有效.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 临床试验 临床试验
背景情况:
- 在高级非小细胞肺癌 (NSCLC) 中免疫治疗有效性的临床试验数据在与年龄相关的疗效方面不一致.
- 老年人往往在临床试验中没有得到充分的代表,这限制了对免疫疗法在这个人口群体中的益处的理解.
- 免疫检查点抑制剂 (ICI) 代表了NSCLC治疗的重大进展.
研究的目的:
- 评估免疫检查点抑制剂 (ICI) 在患有晚期非小细胞肺癌 (NSCLC) 的老年患者 (≥75岁) 的疗效.
- 为了比较ICI在老年人和年轻NSCLC患者队列之间的整体生存 (OS) 益处.
主要方法:
- 进行了全面的文献审查,直到2024年4月,以确定相关的II或III期随机临床试验.
- 在不同年龄组 (75岁以下和75岁以上) 中提取和分析了整体生存期的危险比率 (HR).
- 计算了HRs (RHR) 的比率,以直接比较年龄组之间的生存结果.
主要成果:
- 对13项随机临床试验的分析显示,在75岁以下的患者中,OS的HR为0.75,在75岁及以上的患者中为0.87.
- 与75岁以下患者相比,75岁及以上患者的综合RHR为1.14,表明在OS益处上没有显著差异 (P=0.697).
- 亚组分析证实了ICI在所有年龄组和患者亚组中具有一致的OS益处.
结论:
- 这次元分析发现,在75岁及以上的患者和75岁以下的患者之间,对于非小细胞肺癌 (NSCLC) 的免疫疗法的疗效没有显著差异.
- 免疫检查点抑制剂 (ICI) 在治疗NSCLC的有效性在不同年龄人口统计学中是一致的.
- 这些发现支持ICI在老年NSCLC患者的使用,解决了临床试验中历史的不足.
更多相关视频
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.0K
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.1K
相关概念视频
01:27Tumor Immunotherapy
493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K